Glenmark USA Launches Milnacipran Hydrochloride Generic

Glenmark Pharmaceuticals USA announced the launch of Milnacipran Hydrochloride Tablets on March 19, 2026. This new generic enters a market where the reference product, Savella®, recorded approximately $102.9 million in sales over the 12 months leading up to January 2026.

New Generic Drug Introduced

Glenmark's U.S. subsidiary has introduced Milnacipran Hydrochloride Tablets in 12.5 mg, 25 mg, 50 mg, and 100 mg strengths. As an authorized generic to Savella® Tablets, the new product aims to offer a more affordable treatment option for individuals managing fibromyalgia.

Significance for Patients and Glenmark

This launch supports Glenmark's strategy to expand its presence in the competitive U.S. generics market. It provides patients with a cost-effective treatment for fibromyalgia, a condition that impacts many individuals. The move also diversifies Glenmark's U.S. product offerings and establishes a new revenue source.

About Milnacipran and Savella

Glenmark Pharmaceuticals strategically focuses on introducing generics in regulated markets such as the U.S. The company has a track record of broadening its U.S. product line, including recent launches of other complex generics. Milnacipran, sold as Savella, is an SNRI primarily approved in the U.S. to help manage fibromyalgia, easing pain and fatigue.

Business Impact

Shareholders can expect a new revenue stream from the Milnacipran Hydrochloride market, though it will be competitive. This product addition strengthens Glenmark's position in the U.S. generics sector. The company will now compete within a segment previously led by the branded Savella and its existing generics.

Potential Challenges and Past Issues

Glenmark's Milnacipran Hydrochloride Tablets are approved solely for the indications specified on the product label, which may be narrower than those of Savella. Data from IQVIA used for market analysis might also limit a complete comparison for indications outside the reference drug's listing. In the past, Glenmark has received FDA warning letters regarding manufacturing practices. However, its facility in Monroe, North Carolina, was classified as Voluntary Action Indicated in late 2025, permitting a resumption of commercial manufacturing. Additionally, a provision for a U.S. antitrust lawsuit settlement was made in the first quarter of fiscal year 2026.

Key Competitors in the Generics Market

Glenmark competes against other major generic pharmaceutical companies in the U.S. These include Teva Pharmaceuticals, a global leader in generics; Viatris Inc., formed by the Mylan and Pfizer Upjohn merger, which holds substantial market share; and Cipla, an Indian multinational with a strong U.S. generics presence. These firms are recognized for their broad portfolios and aggressive market strategies.

Market Size Data

The U.S. market for Savella® Tablets and comparable generic versions generated approximately $102.9 million in sales for the 12-month period concluding in January 2026.

Looking Ahead

Investors will likely monitor the initial sales performance and market adoption of the new generic. Tracking competitor reactions, pricing strategies, and any future regulatory developments or potential label expansions will also be key.